GlassScriptPhysician profile
Sylvia L Krueger
NPI 1437152691
$8,434.97
in general payments reported to CMS, 2019-2025
60 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,460 · 2020: $659 · 2021: $37.68 · 2022: $234 · 2023: $1,398 · 2024: $1,395 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.58 |
| Education | $187.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $831.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $775.09 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $677.46 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $395.03 | 2019-2025 | |
| Amgen INC. | $320.74 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| Incyte Corporation | $304.92 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $276.83 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $275.52 | 2019-2025 | Perjeta, Phesgo, Tecentriq |
| Celgene Corporation | $256.09 | 2019-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $224.75 | 2019-2025 | Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $224.30 | 2019-2024 | Opdivo, Opdualag, Augtyro |
| Astellas Pharma US INC | $203.12 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Daiichi Sankyo INC. | $189.91 | 2020-2025 | Enhertu |
| Exelixis INC. | $180.32 | 2019-2024 | Cabometyx |
| Tersera Therapeutics LLC | $173.85 | 2019-2024 | Zoladex, Xermelo |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Krueger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.